SCHEMBL3254074

SCHEMBL3254074

CCN(C(=O)O)[Si](C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.34
FFAR3 O14843 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GLA P06280 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11678374 0.78 CHRM1 (0.38) ALDH1A1
SCHEMBL3314937 0.76 ALDH1A1 (0.32) ALDH1A1TSHR
SCHEMBL6672411 0.76 LMNA (0.33) LMNAFFAR3ALDH1A1
SCHEMBL467915 0.74 LMNA (0.32) LMNAFFAR3ALDH1A1GLATSHR
SCHEMBL22680921 0.74 ALDH1A1 (0.31) ALDH1A1GLATSHR
SCHEMBL1582911 0.74
SCHEMBL11897940 0.72 KDM4E (0.31)
SCHEMBL11897939 0.72 KDM4E (0.31)
SCHEMBL11134692 0.70 ALDH1A1 (0.40) LMNAALDH1A1TSHR
SCHEMBL17224669 0.70 CHRM2 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0169144-B1 PROCESS FOR THE PREPARATION OF 7-AMINO AND 7-SUBSTITUTED AMINO-DESACETOXYCEPHALOSPORINS FROM THE CORRESPONDING 6-SUBSTITUTED AMINO PENICILLIN SULPHOXIDES GEMA S.A. (ES) 1990-06-06 EP claimed
EP-0017170-B1 IMPROVED PROCESS FOR THE PREPARATION OF CEPHAMYCIN ANTIBIOTICS MERCK & CO. INC. (US) 1983-04-13 EP claimed
CN-115348959-A Heteroaryl compounds and their therapeutic use in disorders associated with altered beta-glucocerebrosidase activity 增益治疗股份有限公司 2022-11-15 CN disclosed
US-20220127271-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) 2022-04-28 US disclosed
EP-3878853-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE Shanghai Ringene BioPharma Co., Ltd. (CN) 2021-09-15 EP disclosed
EP-2885300-A1 TRIS(HETERO)ARYLPYRAZOLES AND USE THEREOF AiCuris GmbH & Co. KG (DE) 2015-06-24 EP disclosed
WO-2014027112-A1 TRIS(HETERO)ARYLPYRAZOLES AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2014-02-20 WO disclosed
EP-2181996-A1 Aminopiperidine derivatives GLAXO GROUP LIMITED (GB) 2010-05-05 EP disclosed
US-20100081650-A1 Antimicrobial Compounds AXTEN JEFFREY MICHAEL 2010-04-01 US disclosed
US-7622481-B2 Antibacterial compounds GLAXO GROUP LIMITED (GB) 2009-11-24 US disclosed
US-7534793-B2 Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity SMITHKLINE BEECHAM P.L.C. (GB) 2009-05-19 US disclosed
EP-1051413-A1 QUINOLINE DERIVATIVES AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2000-11-15 EP disclosed
WO-2000043383-A1 PIPERIDINYLQUINOLINES AS PROTEIN TYROSINE KINASE INHIBITORS SMITHKLINE BEECHAM P.L.C. (GB) 2000-07-27 WO disclosed
WO-2000021948-A1 NAPHTHRYDINE COMPOUNDS AND THEIR AZAISOSTERIC ANALOGUES AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2000-04-20 WO disclosed
WO-2000021952-A1 QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2000-04-20 WO disclosed
WO-1999037635-A1 QUINOLINE DERIVATIVES AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 1999-07-29 WO disclosed
US-5190922-A Antiinflammatory ABBOTT LABORATORIES (US) 1993-03-02 US disclosed
WO-1992021361-A1 TERMINALLY MODIFIED TRI-, TETRA- AND PENTAPEPTIDE ANAPHYLATOXIN RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 1992-12-10 WO disclosed
US-4107432-A ANTIBIOTICS MERCK & CO., INC. (US) 1978-08-15 US disclosed
US-4058661-A 7-Diacyl cephalosporins MERCK & CO., INC. (US) 1977-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127271-A1 NITROGEN-CONTAINING FUSED HETEROCYCLIC SHP2 INHIBITOR COMPOUND, PREPARATION METHOD, AND USE PTPN1, PTPN7, PTPN9 LMNA 4854/4885FFAR3 3973/4885ALDH1A1 3157/4885
US-20100081650-A1 Antimicrobial Compounds ELANE, NISCH, PIGS LMNA 2961/4885FFAR3 3710/4885ALDH1A1 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.